about
Chemically engineered persistent luminescence nanoprobes for bioimagingNanoprobes with near-infrared persistent luminescence for in vivo imaging.Functionalized single-walled carbon nanotubes containing traces of iron as new negative MRI contrast agents for in vivo imaging.Optical imaging of luminescence for in vivo quantification of gene electrotransfer in mouse muscle and knee.Poloxamer bioadhesive hydrogel for buccal drug delivery: Cytotoxicity and trans-epithelial permeability evaluations using TR146 human buccal epithelial cell line.Evaluation of Nonradiative Clinical Imaging Techniques for the Longitudinal Assessment of Tumour Growth in Murine CT26 Colon Carcinoma.Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer.Bioavailability of polyphenol liposomes: a challenge aheadFine tuning of mixed ionic and hydrogen bond interactions for plasmid delivery using lipoplexes.A suicide gene therapy combining the improvement of cyclophosphamide tumor cytotoxicity and the development of an anti-tumor immune response.In vitro targeting of avidin-expressing glioma cells with biotinylated persistent luminescence nanoparticles.Synthesis and functionalization of persistent luminescence nanoparticles with small molecules and evaluation of their targeting ability.Synthesis and structure-activity relationships of constrained heterocyclic analogues of combretastatin A4.Design, synthesis, and biological evaluation of the first podophyllotoxin analogues as potential vascular-disrupting agents.Structure-activity relationships of indole compounds derived from combretastatin A4: synthesis and biological screening of 5-phenylpyrrolo[3,4-a]carbazole-1,3-diones as potential antivascular agents.Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3',4',5'-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents.Cationic microbubbles and antibiotic-free miniplasmid for sustained ultrasound-mediated transgene expression in liver.Neutral postgrafted colloidal particles for gene delivery.Lipopolythiourea transfecting agents: lysine thiourea derivatives.Cyanine derivative as a suitable marker for thermosensitive in situ gelling delivery systems: In vitro and in vivo validation of a sustained buccal drug delivery.The in vivo activation of persistent nanophosphors for optical imaging of vascularization, tumours and grafted cells.In vivo electrochemical detection of nitric oxide in tumor-bearing mice.Metabolism of Flavone-8-acetic Acid in Mice.Self-emulsifying drug delivery system developed by the HLB-RSM approach: Characterization by transmission electron microscopy and pharmacokinetic study.Evaluation of Antivascular Combretastatin A4 P Efficacy Using Supersonic Shear Imaging Technique of Ectopic Colon Carcinoma CT26.Colon Tumor Growth and Antivascular Treatment in Mice: Complementary Assessment with MR Elastography and Diffusion-weighted MR ImagingLaAlO 3 :Cr 3+ , Sm 3+ : Nano-perovskite with persistent luminescence for in vivo optical imagingPreparation and Evaluation of Multiple Nanoemulsions Containing Gadolinium (III) Chelate as a Potential Magnetic Resonance Imaging (MRI) Contrast AgentNanoemulsion formulation of fisetin improves bioavailability and antitumour activity in miceMuscle transfection and permeabilization induced by electrotransfer or pluronic® L64Paired study by optical imaging and MRILipopolythioureas: A New Non-Cationic System for Gene TransferIntramuscular plasmid DNA electrotransfer: biodistribution and degradationAnionic polyethyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation timeAssessment of the targeting specificity of a fluorescent albumin conceived as a preclinical agent of the liver functionLocal immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinomaDegradation of ZnGa2O4:Cr3+ luminescent nanoparticles in lysosomal-like mediumIn Situ Gelling Ophthalmic Drug Delivery System for the Optimization of Diagnostic and Preoperative Mydriasis: In Vitro Drug Release, Cytotoxicity and Mydriasis Pharmacodynamics
P50
Q28069326-45B0BB19-5074-42DD-A648-D097410F291EQ30479577-07B4AB60-3439-45CB-814A-5BCAAD303966Q34204245-6787EBA1-CDD5-4E25-BDD7-BC8513E98025Q34521794-E851E84C-8CB7-4924-980B-BAF2526FEC5EQ35786916-DF0565E1-456E-4C91-B240-FEBA342FBB12Q37019989-0793CC03-FA64-451F-AADD-ACE47EF533CDQ37191409-45A69AB8-5120-4208-8A95-62659F8D1D53Q37332632-22BA8AE5-FBC9-4CCC-A233-47AC6924BDD2Q38935320-21B8B44E-6376-40AD-9AE0-D3631DC97359Q39001278-45836E31-C1D2-4027-A15B-CD1061C86BC8Q39411225-7578AC4C-33E4-4426-8863-8A2E717C1C80Q39497986-9B3603C8-6A3F-44E8-80C3-2CB096255BC8Q39512017-033655C2-7ED1-4D5A-9E32-500BA1482FC0Q39639346-52C95EE0-8E27-4663-B7B3-21A10E7952EAQ39694682-8FE70DB7-9D5B-4A78-A7A8-8C31D22B1ACBQ39967868-995162E4-52F6-4B72-9DCD-2958AB38A7DFQ40122162-D5D4BAF9-98AD-48FB-950E-C98AABA0ECF6Q42814634-D161C7BC-9EDD-4AEE-8A86-FF4A685C0E1FQ46863838-25A5998E-30F2-4A0B-A67E-5A65120C16EAQ49574263-AA752888-C53F-473E-9B6E-86B9A6C5DC73Q50476268-D7D73116-499A-4BD0-B67C-6EB242BF4841Q51077099-114395CC-B621-44FA-988C-7E33099AEE20Q51611168-CAF146E5-D89B-4A63-85B9-C7410BFB8A66Q53546276-91DE8A87-6B22-4142-A4C8-064F3DA16C51Q53759519-0E358ADF-071E-4615-B650-1ADEE3F86122Q57782496-BF43FD28-53AB-440B-8FE9-013CA2B09AD0Q58479780-E168AE04-8C6C-4897-9437-5BEC719943A5Q58479805-F98538EC-B8E7-4311-8FC5-9E26D72B4CAFQ58479821-53252577-648B-4A5A-9D1A-636FDC24BDB8Q58479844-C112923B-F294-43A5-8D0F-798E1773DC99Q58479848-5FF0F128-27A2-482F-BD95-C8E1147D7C52Q58479852-D7F7789F-0507-45DF-8294-99B29C7581B1Q58479854-18FFBF25-439E-4313-A039-AF56B3729D3CQ58586247-53E0BBC3-07D0-4DF7-BDF0-830C4E4EB479Q61798268-DA849700-AC5E-4056-ADD8-3180926D603CQ92466584-A8D1820A-2D7C-44D6-807F-3A4B0104878BQ93189731-40E4C540-C555-48F2-AA6C-184AD5EB2426
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Johanne Seguin
@ast
Johanne Seguin
@en
Johanne Seguin
@es
Johanne Seguin
@nl
Johanne Seguin
@sl
type
label
Johanne Seguin
@ast
Johanne Seguin
@en
Johanne Seguin
@es
Johanne Seguin
@nl
Johanne Seguin
@sl
prefLabel
Johanne Seguin
@ast
Johanne Seguin
@en
Johanne Seguin
@es
Johanne Seguin
@nl
Johanne Seguin
@sl
P106
P31
P496
0000-0001-5689-7046